A convergent research narrative is emerging that repositions Alzheimer's disease not as a disorder initiated by amyloid and tau, but as the downstream consequence of an earlier, self-perpetuating bioenergetic and genomic instability cascade. The sequence—energy failure and mitochondrial dysfunction driving ROS accumulation and NAD+ depletion, which impair SIRT1 signaling and produce redox imbalance/oxidative stress and redox failure—precedes and causes classic hallmarks (amyloid plaques, tau tangles). Cellular senescence and neurodegeneration are framed as interdependent drivers within this cycle, with DNA damage acting as both trigger and consequence of senescence. This reframes AD pathogenesis around upstream cellular stress-response failures rather than proteinopathy alone, positioning mitochondrial and redox biology, chromatin architecture changes, and transcriptomic senescence signatures as candidate early biomarkers and intervention points.
Central to this trend is APOE genotype as a determinant of cellular resilience versus vulnerability along this cascade. Work from the Buck Institute using isogenic human iPSC-derived neurons (both GABAergic and glutamatergic subtypes) and validated in APOE2-targeted replacement mice demonstrates that APOE2—already known as a longevity allele—actively promotes DNA repair and DNA damage-signaling pathways, resulting in markedly lower DNA damage and resistance to cellular senescence compared to APOE3 (isogenic control) and APOE4. APOE4, conversely, is associated with senescence-promoting processes and DNA damage linked to altered ribosomal RNA expression. This allele-stratified contrast provides a mechanistic bridge between a well-established genetic risk factor and the emerging senescence/genomic-instability model of neurodegeneration, suggesting APOE2's protective effect against AD and its association with exceptional human longevity operate substantially through enhanced DNA repair capacity rather than solely through lipid or amyloid handling.
The therapeutic trajectory implied by this cluster moves toward APOE-based strategies (e.g., astrocytic APOE3-Christchurch expression) and DNA-repair-pathway activation as interventions to blunt amyloid-β pathology and broader neurodegeneration, alongside interest in restoring NAD+/SIRT1 axis function and glymphatic/CSF-ISF clearance (AQP4-mediated) as complementary mechanisms for waste and redox homeostasis. Collectively, this points to a shift from late-stage anti-amyloid therapeutics toward early, genotype-informed interventions targeting senescence resistance, DNA repair enhancement, and mitochondrial/redox stabilization—using patient-derived fibroblast and iPSC transcriptomic signatures and chromatin-based biomarkers to enable earlier risk stratification and mechanism-based prevention strategies, particularly for APOE4 carriers who lack the innate protective machinery seen in APOE2 carriers.